Deep learning analysis of serial digital breast tomosynthesis images in a prospective cohort of breast cancer patients who received neoadjuvant chemotherapy.

Artificial intelligence Breast cancer Breast tomosynthesis Imaging Mammography Neoadjuvant chemotherapy

Journal

European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411

Informations de publication

Date de publication:
14 Jul 2024
Historique:
received: 27 11 2023
revised: 15 05 2024
accepted: 12 07 2024
medline: 20 7 2024
pubmed: 20 7 2024
entrez: 19 7 2024
Statut: aheadofprint

Résumé

Different imaging tools, including digital breast tomosynthesis (DBT), are frequently used for evaluating tumor response during neoadjuvant chemotherapy (NACT). This study aimed to explore whether using artificial intelligence (AI) for serial DBT acquisitions during NACT for breast cancer can predict pathological complete response (pCR) after completion of NACT. A total of 149 women (mean age 53 years, pCR rate 22 %) with breast cancer treated with NACT at Skane University Hospital, Sweden, between 2014 and 2019, were prospectively included in this observational cohort study (ClinicalTrials.gov: NCT02306096). DBT images from both the cancer and contralateral healthy breasts acquired at three time points: pre-NACT, after two cycles of NACT, and after the completion of six cycles of NACT (pre-surgery) were analyzed. The deep learning AI system used to predict pCR consisted of a backbone 3D ResNet and an attention and prediction module. The GradCAM method was used to obtain insights into the model decision basis through a quantitative analysis of the importance maps on the validation set. Moreover, specific model choices were motivated by ablation studies. The AI model reached an AUC of 0.83 (95% CI: 0.63-1.00) (test set). The spatial correlation of importance maps for input volumes from the same patient but at different time points was high, possibly indicating that the model focuses on the same areas during decision-making. We demonstrate a high discriminative performance of our algorithm for predicting pCR/non-pCR. Availability of larger datasets would permit more comprehensive training of the models and more rigorous evaluation of their prediction performance for future patients.

Identifiants

pubmed: 39029241
pii: S0720-048X(24)00340-1
doi: 10.1016/j.ejrad.2024.111624
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02306096']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111624

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Daniel Förnvik (D)

Medical Radiation Physics, Department of Translational Medicine, Lund University, Skane University Hospital, Malmö, Sweden; Department of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden. Electronic address: daniel.fornvik@med.lu.se.

Signe Borgquist (S)

Department of Oncology, Aarhus University Hospital/Aarhus University, Denmark; Division of Oncology, Department of Clinical Sciences, Lund University, Sweden. Electronic address: signe.borgquist@auh.rm.dk.

Måns Larsson (M)

Eigenvision AB, Malmö, Sweden. Electronic address: mans@eigenvision.se.

Sophia Zackrisson (S)

Department of Translational Medicine, Diagnostic Radiology, Lund University and Department of Radiology, Skane University Hospital, Malmö, Sweden. Electronic address: sophia.zackrisson@med.lu.se.

Ida Skarping (I)

Division of Oncology, Department of Clinical Sciences, Lund University, Sweden; The Department of Clinical Physiology and Nuclear Medicine, Skane University Hospital, Lund, Sweden. Electronic address: ida.skarping@med.lu.se.

Classifications MeSH